Cargando…

Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID‐19 pandemic

AIMS: This study aimed to evaluate the impact of coronavirus disease 2019 (Covid‐19) outbreak on admissions for acute myocardial infarction (AMI) and related mortality, severity of presentation, major cardiac complications and outcome in a tertiary‐care university hospital in Berlin, Germany. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Primessnig, Uwe, Pieske, Burkert M., Sherif, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835606/
https://www.ncbi.nlm.nih.gov/pubmed/33283476
http://dx.doi.org/10.1002/ehf2.13075
_version_ 1783642564724785152
author Primessnig, Uwe
Pieske, Burkert M.
Sherif, Mohammad
author_facet Primessnig, Uwe
Pieske, Burkert M.
Sherif, Mohammad
author_sort Primessnig, Uwe
collection PubMed
description AIMS: This study aimed to evaluate the impact of coronavirus disease 2019 (Covid‐19) outbreak on admissions for acute myocardial infarction (AMI) and related mortality, severity of presentation, major cardiac complications and outcome in a tertiary‐care university hospital in Berlin, Germany. METHODS AND RESULTS: In a single‐centre cross‐sectional observational study, we included 355 patients with AMI containing ST‐elevation or non‐ST‐elevation myocardial infarction (STEMI or NSTEMI), admitted for emergency cardiac catheterization between January and April 2020 and the equivalent time in 2019. During the early phase of the Covid‐19 pandemic (e‐COV) in Berlin (March and April 2020), admissions for AMI halved compared with those in the pre‐Covid‐19 time (January and February 2020; pre‐COV) and with those in the corresponding months in 2019. However, mortality for AMI increased substantially from 5.2% pre‐COV to 17.7% (P < 0.05) during e‐COV. Severity of presentation for AMI was more pronounced during e‐COV [increased levels of cardiac enzymes, reduced left ventricular ejection fraction (LVEF), an increase in the need of inotropic support by 25% (P < 0.01)], while patients' demographic and angiographic characteristics did not differ between pre‐COV and e‐COV. Time from symptom onset to first medical contact was prolonged in all AMI during e‐COV (presentation > 72 h +21% in STEMI, p = 0.04 and presentation > 72 h in NSTEMI +22%, p = 0.02). Door to balloon time was similar in STEMI patients, while time from first medical contact to revascularization was significantly delayed in NSTEMI patients (p = 0.02). Major cardiac complications after AMI occurred significantly more often, and cardiac recovery was worse in e‐COV than in pre‐COV, demonstrated by a significantly lower LVEF (39 ± 16 vs. 46 ± 16, p < 0.05) at hospital discharge and substantially higher NTproBNP levels. CONCLUSIONS: The Covid‐19 outbreak affects hospital admissions for acute coronary syndromes. During the first phase of the pandemia, significantly less patients with AMI were admitted, but those admitted presented with a more severe phenotype and had a higher mortality, more complications, and a worse short‐term outcome. Therefore, our data indicate that Covid‐19 had relevant impact on non‐infectious disease states, such as acute coronary syndromes.
format Online
Article
Text
id pubmed-7835606
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78356062021-02-01 Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID‐19 pandemic Primessnig, Uwe Pieske, Burkert M. Sherif, Mohammad ESC Heart Fail Original Research Articles AIMS: This study aimed to evaluate the impact of coronavirus disease 2019 (Covid‐19) outbreak on admissions for acute myocardial infarction (AMI) and related mortality, severity of presentation, major cardiac complications and outcome in a tertiary‐care university hospital in Berlin, Germany. METHODS AND RESULTS: In a single‐centre cross‐sectional observational study, we included 355 patients with AMI containing ST‐elevation or non‐ST‐elevation myocardial infarction (STEMI or NSTEMI), admitted for emergency cardiac catheterization between January and April 2020 and the equivalent time in 2019. During the early phase of the Covid‐19 pandemic (e‐COV) in Berlin (March and April 2020), admissions for AMI halved compared with those in the pre‐Covid‐19 time (January and February 2020; pre‐COV) and with those in the corresponding months in 2019. However, mortality for AMI increased substantially from 5.2% pre‐COV to 17.7% (P < 0.05) during e‐COV. Severity of presentation for AMI was more pronounced during e‐COV [increased levels of cardiac enzymes, reduced left ventricular ejection fraction (LVEF), an increase in the need of inotropic support by 25% (P < 0.01)], while patients' demographic and angiographic characteristics did not differ between pre‐COV and e‐COV. Time from symptom onset to first medical contact was prolonged in all AMI during e‐COV (presentation > 72 h +21% in STEMI, p = 0.04 and presentation > 72 h in NSTEMI +22%, p = 0.02). Door to balloon time was similar in STEMI patients, while time from first medical contact to revascularization was significantly delayed in NSTEMI patients (p = 0.02). Major cardiac complications after AMI occurred significantly more often, and cardiac recovery was worse in e‐COV than in pre‐COV, demonstrated by a significantly lower LVEF (39 ± 16 vs. 46 ± 16, p < 0.05) at hospital discharge and substantially higher NTproBNP levels. CONCLUSIONS: The Covid‐19 outbreak affects hospital admissions for acute coronary syndromes. During the first phase of the pandemia, significantly less patients with AMI were admitted, but those admitted presented with a more severe phenotype and had a higher mortality, more complications, and a worse short‐term outcome. Therefore, our data indicate that Covid‐19 had relevant impact on non‐infectious disease states, such as acute coronary syndromes. John Wiley and Sons Inc. 2020-12-06 /pmc/articles/PMC7835606/ /pubmed/33283476 http://dx.doi.org/10.1002/ehf2.13075 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research Articles
Primessnig, Uwe
Pieske, Burkert M.
Sherif, Mohammad
Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID‐19 pandemic
title Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID‐19 pandemic
title_full Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID‐19 pandemic
title_fullStr Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID‐19 pandemic
title_full_unstemmed Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID‐19 pandemic
title_short Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID‐19 pandemic
title_sort increased mortality and worse cardiac outcome of acute myocardial infarction during the early covid‐19 pandemic
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835606/
https://www.ncbi.nlm.nih.gov/pubmed/33283476
http://dx.doi.org/10.1002/ehf2.13075
work_keys_str_mv AT primessniguwe increasedmortalityandworsecardiacoutcomeofacutemyocardialinfarctionduringtheearlycovid19pandemic
AT pieskeburkertm increasedmortalityandworsecardiacoutcomeofacutemyocardialinfarctionduringtheearlycovid19pandemic
AT sherifmohammad increasedmortalityandworsecardiacoutcomeofacutemyocardialinfarctionduringtheearlycovid19pandemic